Shareholders reject proposed preferential issue of convertible warrants
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 3.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Choksi Laboratories informed BSE that its proposed preferential issue of convertible warrants was not approved by shareholders at the Extra-Ordinary General Meeting held on October 17, 2026. Promoters and the proposed allottees abstained from voting. The company will not proceed with the issue and has requested BSE to close the in-principle approval application.
Negative: company cannot raise capital through this route. Shareholder rejection may signal concerns over dilution, pricing, or the identity of allottees.